Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 What Are Social Determinants of Health and How Do They Affect... July 22, 2021 Police Officer Has Bulletproof Vest to Thank for Helping Her Discover... June 23, 2021 Dad With Cancer Escorts His Autistic Son To School, With The... August 13, 2019 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... Reflections from our chief scientist: The rise of the whole organism
